The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.30
Bid: 3.30
Ask: 3.50
Change: 0.00 (0.00%)
Spread: 0.20 (6.061%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.30
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)

19 Oct 2023 08:38

RNS Number : 6649Q
Panmure Gordon (UK) Limited
19 October 2023
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Panmure Gordon (UK) Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Allergy Therapeutics plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Allergy Therapeutics plc

(d) Date dealing undertaken:

18 Oct 2023

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

0.1p ordinary

Purchase

 

180,000

0.0127

 

0.0127

 

0.1p ordinary

Sales

1,020,000

0.014

 

0.0125

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing, or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

 

Date of disclosure:

19/10/2023

Contact name:

Freddie Wooding

Telephone number:

+44 (0)20 7886 2969

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FERFZMMGNLVGFZG
Date   Source Headline
15th Jan 20077:00 amRNSNotice of Results
12th Dec 200611:59 amRNSHolding(s) in Company
11th Dec 20063:45 pmRNSHolding(s) in Company
7th Dec 20063:12 pmRNSDirector/PDMR Shareholding
7th Dec 20067:02 amRNSResearch Update
5th Dec 20062:30 pmRNSTotal Voting Rights
6th Nov 200612:12 pmRNSDirector/PDMR Shareholding
3rd Nov 20069:20 amRNSResult of AGM
2nd Nov 200611:39 amRNSDirector/PDMR Shareholding
27th Oct 200610:58 amRNSDirector/PDMR Shareholding
11th Oct 20067:00 amRNSClinical Trials
12th Sep 20067:04 amRNSFinal Results
19th Jul 20067:01 amRNSClinical update
14th Jul 20067:01 amRNSTrading Statement
7th Jul 20064:17 pmRNSDirector/PDMR Shareholding
4th Jul 20067:00 amRNSClinical update
3rd Jul 20064:08 pmRNSHolding(s) in Company
21st Jun 20067:00 amRNSClinical update
11th May 20067:02 amRNSApproval of Vaccine patent
10th May 20063:43 pmRNSDirector/PDMR Shareholding
8th May 200611:44 amRNSHolding(s) in Company
4th May 200612:06 pmRNSEGM Statement
10th Apr 20067:02 amRNSIssue of Equity
28th Mar 20064:28 pmRNSHolding(s) in Company
27th Mar 20067:01 amRNSInterim Results
24th Mar 20067:02 amRNSClinical update
16th Mar 20069:29 amRNSNotice of Results-Amendment
6th Mar 20067:03 amRNSClinical update
1st Mar 20069:30 amRNSNotice of Results
27th Feb 20061:02 pmRNSHolding(s) in Company
9th Jan 20063:32 pmRNSHolding(s) in Company
15th Dec 20057:01 amRNSDirector/PDMR Shareholding
6th Dec 20054:17 pmRNSHolding(s) in Company
2nd Dec 20057:01 amRNSClinical update
22nd Nov 20057:03 amRNSDirectorate change and update
17th Nov 20051:08 pmRNSHolding(s) in Company
14th Nov 20057:01 amRNSChange of Adviser
7th Nov 20057:00 amRNSDirectorate Change
4th Nov 20053:05 pmRNSResult of AGM
25th Oct 20052:27 pmRNSDirector/PDMR Shareholding
13th Sep 20057:01 amRNSFinal Results
24th Aug 20057:00 amRNSChange of Adviser
18th Jul 20057:01 amRNSTrading Statement
11th May 20057:00 amRNSHolding(s) in Company
10th May 20057:01 amRNSClearance for vaccine studies
3rd May 20053:04 pmRNSHolding(s) in Company
21st Apr 200512:12 pmRNSHolding(s) in Company
14th Apr 20058:59 amRNSHolding(s) in Company
21st Mar 20054:22 pmRNSHolding(s) in Company
21st Mar 20052:54 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.